

References

- Abbas A.K., Murphy K.M., and Sher A. (1996). Functional diversity of helper T lymphocytes. *Nature* **383**: 787-93.
- Aliprantis A.O., Diez-Roux G., Mulder L.C., Zychlinsky A., and Lanng R.A., (1996). Do macrophages kill through apoptosis? *Immunol Today*. **17**: 573-576.
- Allendoerfer R. and Deepe G.S. Jr. (1998). Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. *J Immunol*. **160**: 6072-82.
- Alwine J.C., Kemp D.J., Stark G.R. (1977). Method for detection of specific RNAs in agarose gels by transfer to diazobenzyloxymethyl-paper and hybridization with DNA probes. *Proc Natl Acad Sci USA*. **74**: 5350-4.
- Andersen P., (1997). Host responses and antigens involved in protective immunity to *Mycobacterium tuberculosis*. *Scand J Immunol*. **45**: 115-131.
- Andersen R.J. (1929^a). The chemistry of lipoids of the tubercle bacilli. VII Analysis of the soft wax from tubercle bacilli. *J Biol Chem*. **85**: 227-328.
- Andersen R.J. (1929^b). The chemistry of lipoids of the tubercle bacilli. VIII Concerning the unsaponifiable wax. *J Biol Chem*. **85**: 329-348.
- Anderson L.J., Jarrett W.F., Jarrett O., and Laird H.M. (1971). Feline leukemia-virus infection of kittens: mortality associated with atrophy of the thymus and lymphoid depletion. *J Natl Cancer Inst*. **47**: 807-17.
- Andrews C., Swain S.L., and Muralidhar G. (1997). CD4 T cell anergy in murine AIDS: costimulation via CD28 and the addition of IL-12 are not sufficient to rescue anergic

CD4 T cells. *J Immunol.* **159**: 2132-8.

Applied Biosystems (2000). **Theory of operation** in ABI Prism® 7700 user's manual. D1-D22.

Applied Biosystems at [http:// www.appliedbiosystems.com](http://www.appliedbiosystems.com)

Aung H., Toossi Z., Wisnieski J.J., Wallis R.S., Culp L.A., Phillips N.B., Phillips M., Averill L.E., Daniel T.M., and Ellner J.J. (1996). Induction of monocyte expression of tumor necrosis factor alpha by the 30-kD alpha antigen of *Mycobacterium tuberculosis* and synergism with fibronectin. *J Clin Invest.* **98**: 1261-8.

Averill L., Toossi Z., Aung H., Boom W.H., and Ellner J.J. (1995). Regulation of production of tumor necrosis factor alpha in monocytes stimulated by the 30-kilodalton antigen of *Mycobacterium tuberculosis*. *Infect Immun.* **63**: 3206-8.

Av-Gay Y. and Sobouti R. (2000). Cholesterol is accumulated by mycobacteria but its degradation is limited to non-pathogenic fast-growing mycobacteria. *Can J Microbiol.* **46**: 826-31.

Avrameas S. (1969^a). Coupling of enzymes to proteins with glutaraldehyde. Use of the conjugates for the detection of antigens and antibodies. *Immunochemistry.* **6**: 43-52.

Avrameas S. (1969^b). Indirect immunoenzyme techniques for the intracellular detection of antigens. *Immunochemistry.* **6**: 825-31.

Avrameas S. (1970). Immunoenzyme techniques: enzymes as markers for the localization of antigens and antibodies. *Int Rev Cytol.* **27**: 49-85.

Avrameas S. and Guilbert B. (1971). A method for quantitative determination of cellular immunoglobulins by enzyme-labeled antibodies. *Eur J Immunol.* **1**: 394-6.

Badley R.A., Drake R.A., Shanks I.A., Smith A.M., and Stephenson P.R. (1987). Optical biosensors for immunoassays: the fluorescence capillary-fill device. *Philos Trans R Soc Lond B Biol Sci.* **316**: 143-60.

Barksdale L. and Kim K.S. (1977). Mycobacterium. *Bacteriol Rev.* **41**: 217-372.

Barnes P.F., Chatterjee D., Abrams J.S., Lu S., Wang E., Yamamura M., Brennan P.J., and Modlin R.L. (1992). Cytokine production induced by Mycobacterium tuberculosis lipoarabinomannan. Relationship to chemical structure. *J Immunol.* **149**:541-7.

Barnes P.F., Fong S-J., Brennan P.J., Twomey P.E., Mazumder A., and Modlin R.L., (1990). Local production of tumour necrosis factor and IFN-gamma in tuberculosis. *J Immunol.***145**: 149-145.

Barnes P.F., Mistry S.D., Cooper C.L., Pirmez C., Rea T.H., and Modlin R.L. (1989). Compartmentalization of a CD4+ T lymphocyte subpopulation in tuberculous pleuritis. *J Immunol.* **142**: 1114-1119.

Barnes P.F. and Modlin R.L.. (1996). Human cellular immune responses to Mycobacterium tuberculosis. *Curr Top Microbiol Immunol.* **215**: 197-219.

Barry C.E. 3rd. (2001). Interpreting cell wall 'virulence factors' of Mycobacterium tuberculosis. *Trends Microbiol.* **9**: 237-41.

Barry C.E. 3rd, Lee R.E., Mdluli K., Sampson A.E., Schroeder B.G., Slayden R.A., and Yuan Y. (1998). Mycolic acids: structure, biosynthesis and physiological functions. *Prog Lipid Res.* **37**: 143-79.

- Becker-A.M. and Hahlbrock K. (1989). Absolute mRNA quantification using the polymerase chain reaction (PCR). A novel approach by a PCR aided transcript titration assay (PATTY). *Nucleic Acids Res.* **17**: 9437-46.
- Beckman E.V., Porcelli S.A., Morita C.T., Behar S.M., Furlong S.T., and Brenner M.B. (1994). Recognition of a lipid antigen by CD1-restricted $\alpha\beta^+$ T cells. *Nature*, **372**: 691-694.
- Behar S.M., Dascher C.C., Grusby M.J., Wang C.R., and Brenner M.B. (1999). Susceptibility of mice deficient in CD1D or TAP1 to infection with *Mycobacterium tuberculosis*. *J Exp Med.* **189**:1973-80.
- Bekierkunst A., Levij I.S., Yarkoni E., Vilkas E., Adam A., and Lederer E. (1969). Granuloma formation induced in mice by chemically defined mycobacterial fractions. *J Bacteriol.* **100**: 95-102.
- Benavides G.R., Hubby B., Grosse R.A., McGraw R.A., and Tarleton R.L. (1995). Construction and use of a multi-competitor gene for RT-PCR using existing primer sets. *Infect Immun.* **62**: 145-56.
- Bendelac A., (1995). CD1: Presenting unusual antigens to unusual T lymphocytes. *Science.* **269**: 185-86
- Bendelac A., Lantz O., Quimby M.E., Yewdell J.W., Bennink J.R., Brutkiewicz R.R. (1995). CD1 recognition by mouse NK1+ T lymphocytes. *Science.* **268**:863-5.
- Bandinelli M., Matteucci D., and Friedman H. (1985). Retrovirus-induced acquired immunodeficiencies. *Adv Cancer Res.* **45**: 125-81.
- Bermudez L.E. and Goodman J. (1996). *Mycobacterium tuberculosis* invades and replicates within type II alveolar cells. *Infect Immun.* **64** :1400-6.

Bermudez L.E., Shelton K., and Young L.S. (1995). Comparison of the ability of *Mycobacterium avium*, *M. smegmatis* and *M. tuberculosis* to invade and replicate within HEp-2 epithelial cells. *Tuber Lung Dis.* **76**:240-7.

Bilyk N. and Holt P.G. (1995). Cytokine modulation of the immunosuppressive phenotype of pulmonary alveolar macrophage populations. *Immunology.* **86**: 231-7.

Blomberg B., Spinaci S., Fourie B., and Laing R. (2001). The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. *Bull World Health Organ.* **79**: 61-8.

Bloom B.R. and Murray C.J. (1992). Tuberculosis: commentary on a reemergent killer. *Science.* **257**: 1055-64.

Bogdan C. and Nathan C. (1993). Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. *Ann N Y Acad Sci.* **685**: 713-39.

Bonecini-Almeida M.G., Chitale S., Boutsikakis I., Geng J., Doo H., He S., and Ho J.L. (1998). Induction of invitro human macrophage anti-mycobacterium tuberculosis activity: requirement for IFN-gamma and primed lymphocytes. *J Immunol.* **160**: 4490-9.

Boom H.W. (1996). The role of T-cell subset in *Mycobacterium tuberculosis* infection. *Infect Agents Dis.* **5**: 73-81.

Boom W.H., Husson R.N., Young R.A., David J.R. and Piessens W.F., (1987). In vivo and in vitro characterization of murine T cell clones reactive to *Mycobacterium tuberculosis*. *Infect Immun,* **55**: 2223-9

Bost K.L. and Clements J.D., (1995). In vivo induction of interleukin-12 mRNA expression after oral immunization with *salmonella dublin* or the B subunit of *Escherichia coli* heat labile enterotoxin. *Infect Immun.* **63**: 1076-83.

Brennan P.J. (1989). Structure of mycobacteria: recent developments in defining cell wall carbohydrates and proteins. *Rev Infect Dis.* **11:** S420-30.

Brennan P.J. and Nikaido H. (1995). The envelope of mycobacteria. *Annu Rev Biochem.* **64:** 29-63.

Butler W.R. Jost K.C. and Kilburn J.O. (1991). Identification of *Mycobacteria* by High-Performance Liquid Chromatography. *J Clin Microbiol.* **29:** 2468-72.

Calabi F. and Bradbury A. (1991). The CD1 system. *Tissue Antigens.* **37:** 1-9.

Calabi F., Jarvis J.M., Martin L., and Milstein C. (1989). Two classes of CD1 genes. *Eur J Immunol.* **19:** 285-92.

Carswell E.A, Old L.J., Kassel R.L., Green S., Fiore N., and Williamson B. (1975). An endotoxin-induced serum factor that causes necrosis of tumors. *Proc Natl Acad Sci USA.* **72:** 3666-70.

Centres for Disease Control and Prevention-USA, (1994). Estimates of future global tuberculosis morbidity and mortality. *JAMA.* **27:** 739 and 741.

Chan S.H., Perussia B., Gupta J.W., Kobayashi M., Popisil M., Young H.A., Wolf S.F., Young D., Clark S.C., and Trinchieri G. (1991). Induction of interferon- γ production by natural killer cell stimulating factor: Characterization of the responding cells and synergy with other inducers. *J Exp Med.* **173:** 869-75.

Chan SH, Kobayashi M, Santoli D, Perussia B, Trinchieri G. (1992). Mechanisms of IFN-gamma induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. *J Immunol.* **148:** 92-8.

Chantry D., Turner M., Brennan F., Kingsbury A., and Feldman M. (1990) Granucyte macrophage colony stimulating factor induces both HLA-DR expression and cytokine production by human monocytes. *Cytokine* **2**: 60-67.

Chantry D., Wineards C.G., Maini R.N., and Feldmann M., (1989). Mechanism of immune complex mediated damage: induction of interleuken 1 by immune complexes and synergy with interferon γ and tumour necrosis factor α . *Eur J Immunol.* **19**: 189-192.

Chaparas S.D. (1982). Immunity in tuberculosis. *Bull World Health Organ.* **60**: 447-62.

Chaparas S.D., Vandiviere H.M., Melvin I., Koch G., and Becker C. (1985). Tuberculin test. Variability with the Mantoux procedure. *Am Rev Respir Dis.* **132**: 175-7.

Chensue S.W., Ruth J.H., Warmington K.S., Lincoln P., and Kunkel S.L., (1995). In vivo regulation of macrophage IL-12 production during type 1 & 2 cytokine-mediating granuloma formation. *J Immunol.* **154**: 5969-5976.

Chermann J.C., Barre-Sinoussi F., Dauguet C., Brun-Vezinet F., Rouzioux C., Rozenbaum W., and Montagnier L. (1983). Isolation of a new retrovirus in a patient at risk for acquired immunodeficiency syndrome. *Antibiot Chemother.* **32**: 48-53.

Chomczynski P. and Sacchi N. (1987). Single step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. *Analyt Biochem.* **162**: 156-159.

Chong C., Bost K.L., and Clements J.D. (1996). Differential production of Interleukin-12 mRNA by murine macrophages in response to viable or killed *Salmonella* spp. *Infect Immun.* **64**: 1906-12.

Chopra I. and Brennan P. (1997). Molecular action of anti-mycobacterial agents. *Tuber Lung Dis.* **78**: 89-98.

Coghlan A. and Concar D. (2001). Is there money in lost memories? *New Sci.* **138**:20-2

Cohn D.L., Catlin B.J., and Harth G., and Petersen K.L., (1990). A 62 dose, 6 months therapy for pulmonary and extra-pulmonary tuberculosis. *Ann Int Med.* **112**: 407-415.

Combs D.L., O'Brien R.J., and Geiter L.J., (1990). USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity and acceptability. *Ann Int Med.* **112**: 397-406.

Comstock G.W. (1982). Epidemiology of tuberculosis. *Am Rev Respir Dis.* **125**: 8-15.

Contreras R., Demolder J., and Fiers W., (1991). Cloning and expression of cytokine genes. In, Balkwill F.R. (ed), *Cytokines, A Practical Approach*, Oxford University Press., Oxford, NY, Tokyo.1-16 .

Cooper A.M., Kipnis A., Turner J., Magram J., Ferrante J., and Orme I.M. (2002). Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. *J Immunol.* **168**: 1322-7.

Cooper A.M., Magram J., Ferrante J., and Orme I.M. (1997). Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis. *J Exp Med.* **186**: 39-45.

Cooper A.M., Roberts A.D., Rhoades E.R., Callahan J.E., Getzy D.M., and Orme I.M. (1995). The role of interleukin-12 in acquired immunity to *Mycobacterium tuberculosis* infection. *Immunology.* **84**: 423-32.

Corbett E.L. and De Cock K.M. (2001). The clinical significance of interactions between HIV and TB: more questions than answers. *Int J Tuberc Lung Dis.* **5**: 205-7.

Cynamon M.H., Zhang Y., Harpster T., Cheng S., and DeStefano M.S. (1999). High-dose isoniazid therapy for isoniazid-resistant murine *Mycobacterium tuberculosis* infection. *Antimicrob Agents Chemother.* **43**: 2922-4.

D'Addario M., Wainberg M.A, and Hiscott J. (1992). Activation of cytokine genes in HIV-1 infected myelomonoblastic cells by phorbol ester and tumor necrosis factor. *J Immunol.* **148**: 1222-9.

Daffe M. and Draper P. (1998). The envelope layers of mycobacteria with reference to their pathogenicity. *Adv Microb Physiol.* **39**: 131-203.

Dalton D.K., Haynes L., Chu C.Q., Swain S.L., and Wittmer S. (2000). Interferon gamma eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. *J Exp Med.* **192**: 117-22.

D'Andrea A. M. Rengaraju M., Valiante N.M., Chehimi J, Kubin M., Aste M., Chan S.H., Kobayashi M., Young D., Nickbarg E. (1992). Production of natural killer cell stimulatory factor (Interleukin-12) by peripheral blood mononuclear cells. *J Exp Med.* **176**: 1387-98.

Dannenber A.M. Jr. (1991) Delayed-type hypersensitivity and cell-mediated immunity in the pathogenesis of tuberculosis. *Immunol Today.* **12**: 17-38

Dannenber A.M. Jr. (1999) Pathogenesis and immunology: Basic concepts, in *Tuberculosis* 4th edition by. David Schlossberg (ed). Springer-Verlag New York. 17-39.

Dannenber AM Jr. (1991). Delayed-type hypersensitivity and cell-mediated immunity in the pathogenesis of tuberculosis. *Immunol Today.* **12**: 228-33

Daugelat S., Ladel C.H., and Kaufmann S.H. (1995). Influence of mouse strain and vaccine viability on T-cell responses induced by *Mycobacterium bovis bacillus* Calmette-Guerin. *Infect Immun.* **63**: 2033-40.

Daugelat S. and Kaufmann S.H. (1996). Role of Th1 and Th2 cells in bacterial infections. *Chem Immunol.* **63**: 66-97.

De Chastellier C. and Thilo L. (1997). Phagosome maturation and fusion with lysosomes in relation to surface property and size of the phagocytic particle. *Eur J Cell Biol.* **74**: 49-62.

De Chastellier C., Lang T., and Thilo L. (1995). Phagocytic processing of the macrophage endoparasite, *Mycobacterium avium*, in comparison to phagosomes which contain *Bacillus subtilis* or latex beads. *Eur J Cell Biol.* **68**: 167-82.

De Libero G., Flesch I., and Kaufmann S.H. (1988). Mycobacteria-reactive Lyt-2+ T cell lines. *Eur J Immunol.* **18**: 59-66.

Desforges B., Hatin I., Akarid K., and Sinet M. (1996). Competitive reverse transcription-polymerase chain reaction for quantifying murine AIDS virus. *J Virol Methods.* **62**: 161-8.

Desmedt M., Rottiers P., Dooms H., Fiers W., and Grooten J. (1998). Macrophages induce cellular immunity by activating Th1 cell responses and suppressing Th2 cell responses. *J Immunol.* **160**: 5300-8.

Denis M. (1991^a). Involvement of cytokines in determining resistance and acquired immunity in murine tuberculosis. *J Leukoc Biol.* **5**: 495-501.

Denis M. (1991^b). Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent *Mycobacterium avium* and to kill avirulent *M. avium*: killing effector mechanism depends on the generation of reactive nitrogen intermediates. *J Leukoc Biol.* **49**: 380-7.

Dick J., and Youngleson S.M. (1994). The design of a case register for tuberculosis. A pilot study in the south-western Cape. *S Afr Med J.* **84**: 621-3.

Dimitropoulos K., Rolland J.M., and Nairn R.C. (1986). Flow cytofluorimetry of fluorescein fluorescence polarization to assay lymphocyte activation. *Biochem Biophys Res Commun.* **136**: 1021-9.

Dinareello C.A. (1991). Interleukin-1 and interleukin-1 antagonism. *Blood.* **77**: 1627-52.

Dinareello C.A., (1984). Interleukin-1 and the pathogenesis of the acute phase response. *N Engl J Med.* **311**: 1413-8.

Ding A.H., C.F. Nathan and D.J. Stuehr. (1988). Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. *J. Immunol.* **141**: 2407-2412.

DiPiro J.T. (1997). Cytokine networks with infection: mycobacterial infections, leishmaniasis, human immunodeficiency virus infection, and sepsis. *Pharmacotherapy.* **17**: 205-23.

Doherty T.M., Giese N., Morse H.C. 3rd, and Coffman R.L. (1997). Modulation of murine AIDS-related pathology by concurrent antibody treatment and coinfection with *Leishmania major*. *J Virol.* **71**: 3702-9.

Doherty T.M., Morse H.C. 3rd, and Coffman R.L. (1995). Modulation of specific T cell responses by concurrent infection with *Leishmania major* and LP-BM5 murine leukemia viruses. *Int Immunol.* **7**: 131-8.

Draper P.,(2000). Lipid biochemistry takes a stand against tuberculosis. *Nature Med.* **6**: 977-8.

Ehlers S., Benini J., Held H.D., Roeck C., Alber G., and Uhlig S. (2001). Alphabeta T cell receptor-positive cells and interferon-gamma, but not inducible nitric oxide synthase, are critical for granuloma necrosis in a mouse model of mycobacteria-induced pulmonary immunopathology. *J Exp Med.* **194**: 1847-59.

Ehlers S., Milke M.E.A., and Hahn H. (1994). Progress in TB research: Robert Koch's dilemma revisited. *Immunol Today.* **15**: 1-4.

Ellner J.J. (1994). Current issues in tuberculosis. *J Lab Clin Med.* **123**: 478-84

Ellner J.J. (1997). Regulation of the human immune response during tuberculosis. *J Lab Clin Med.* **130**: 469-475.

Emoto M., Emoto Y., and Kaufmann S.H.E. (1997). Bacille Calmette Guérin and interleukin-12 downmodulates interleukin-4 producing CD4⁺NK1⁺ T lymphocytes. *Eur J Immunol.* **27**: 183-188.

Etemadi A.H. (1967). The use of pyrolysis gas chromatography and mass spectroscopy in the study of the structure of mycolic acids. *J. of G.C.* **5**: 447-456

Fathman C.G. and Frelinger J.G. (1988). T lymphocyte clones. *Annu Rev Immunol.* **1**: 633-55.

Fätkenheuer G., Taelman H., Lepage P., Schwenk A., and Wenzel R. (1999). The return of tuberculosis. *Diagn Microbiol Infect Dis.* **34**: 139-46

Fehniger T.A., Shah M.H., Turner M.J., VanDeusen J.B., Whitman S.P., Cooper M.A., Suzuki K., Wechser M., Goodsaid .F, and Caligiuri M.A. (1999). Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. *J Immunol.* **162**: 4511-20.

Fenton M.J. and Vermeulen M.W. (1996). Immunopathology of tuberculosis: roles of macrophages and monocytes. *Infect Immun.* **64**: 683-90.

Ferrari G., Langen H., Naito M., and Pieters J. (1999). A coat protein on phagosomes involved in the intracellular survival of mycobacteria. *Cell.* **97**: 435-47.

Flesch I. and Kaufmann S.H.E., (1991). Mechanisms involved in mycobacterial growth inhibition by gamma-interferon activated bone marrow macrophages: Role of reactive nitrogen intermediates. *Infect Immun* **59**: 3213-8

Flesch I., Kaufmann S.H.E., (1987). Mycobacterial growth inhibition by interferon-gamma-activated bone marrow macrophages and susceptibility among strains of *Mycobacterium tuberculosis*. *J Immunol.* **138**: 4408-13.

Flynn J.L. and Chan J. (2001^a). Immunology of tuberculosis. *Annu Rev Immunol.* **19**: 93-129.

Flynn J.L. and Chan J. (2001^b). Tuberculosis: latency and reactivation. *Infect Immun.* **69**: 4195-201.

Flynn, J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., and Bloom B.R. (1993). An essential role for interferon γ in resistance to *Mycobacterium tuberculosis*. *J Exp Med.* **178**: 2249-2254.

Flynn, J.L., Goldstein M.M., Triebold K.J., Sypek J., Wolf S., and Bloom B.R. (1995). IL-12 increases resistance of BALB/c mice to *Mycobacterium tuberculosis* infection. *J Immunol.* **155**: 2515-2524.

Freaney R., McShane A., Keaveny T.V., McKenna M., Rabenstein K., Scheller F.W., Pfeiffer D., Urban G., Moser I., Jobst G., Manz A., Verpoorte E., Widmer M.W., Diamond D., Dempsey E., Saez de Viteri F.J., and Smyth M. (1997). Novel instrumentation for real-time monitoring using miniaturized flow systems with integrated biosensors. *Ann Clin Biochem.* **34**: 291-302.

Fujiwara N., Pan J., Enomoto K., Terano Y., Honda T., and Yano I. (1999). Production and partial characterization of anti-cord factor (trehalose-6,6'-dimycolate) IgG antibody in rabbits recognizing mycolic acid subclasses of *Mycobacterium tuberculosis* or *Mycobacterium avium*. *FEMS Immunol Med Microbiol.* **24**: 141-9.

Gallicchio V.S., Hughes N.K., Tse K.F., Ling J., Gaines H., Bowen T.E., Uluitu M. (1995). Effect of combination interleukin-3 (IL-3) and granulocyte-macrophage colony stimulating factor (GM-CSF) on hematopoiesis administered to retrovirus-infected immunodeficient mice receiving dose-escalation zidovudine (AZT). *Int J Immunopharmacol.* **17**: 865-78.

Garcia I., Miyazaki Y., Marchal G., Lesslauer W., and Vassalli P. (1997). High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: synergistic action of TNF and IFN-gamma in the differentiation of protective granulomas. *Eur J Immunol.* **27**: 3182-90.

Gatfield J. and Pieters J. (2000). Essential role for cholesterol in entry of mycobacteria into macrophages. *Science*. **288**: 1647-50.

Gazzinelli R.T., Hieny S., Wynn T.A., Wolf S., and Sher A. (1993). Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. *Proc Natl Acad Sci USA*. **90**: 6115-9.

Giese N.A., Gazzinelli R.T., Morawetz R.A., and Morse H.C. 3rd. (1995). Role of IL-12 in MAIDS. *Res Immunol*. **146**: 600-5.

Giese N.A., Giese T., and Morse H.C. 3rd. (1994). Murine AIDS is an antigen-driven disease: requirements for major histocompatibility complex class II expression and CD4+ T cells. *J Virol*. **68**: 5819-24.

Gilliland G., Perrin S., Blanchard K., and Bunn H.F. (1990). Analysis of cytokine mRNA and DNA: detection and quantitation by competitive polymerase chain reaction. *Proc Natl Acad Sci USA*. **87**: 2 725-9.

Gilmore G.L., Cowing C., and Mosier D.E. (1993). LP-BM5 murine retrovirus-induced immunodeficiency disease in allogeneic SCID chimeric mice. Inability to recognize a putative viral superantigen does not prevent induction of disease. *J Immunol*. **150**: 185-9.

Giuliani A., Porcelli S.A., Tentori L, Graziani G., Testorelli C., Prete SP., Bussini S., Cappelletti D., Brenner M.B., Bonmassar E., and Aquino A. (1998). Effect of rifampin on CD1b expression and double-negative T cell responses against mycobacteria-derived glycolipid antigen. *Life Sci*. **63**: 985-94.

Glickman S.E., Kilburn J.O., Butler W.R., and Ramos L.S. (1994). Rapid identification of mycolic acid patterns of mycobacteria by high-performance liquid chromatography using pattern recognition software and a Mycobacterium library. *J Clin Microbiol.* **32**: 740-5.

Gomes M.S., Paul S., Moreira A.L., Appelberg R., Rabinovitch M., and Kaplan G. (1999). Survival of Mycobacterium avium and Mycobacterium tuberculosis in acidified vacuoles of murine macrophages. *Infect Immun.* **67**: 3199-206.

Gong J., Stenger S., Zack J.A., Jones B.E., Bristol G.C., Modlin R.L., Morrissey P.J., and Barnes P.F. (1998). Isolation of mycobacterium-reactive CD1-restricted T cells from patients with human immunodeficiency virus infection. *J Clin Invest.* **101**: 383-9.

Goodrum M.A., Siko D.G.R., Niehues T., Eichelbauer D., and Verschoor J.A. (2001). Mycolic acids from *Mycobacterium tuberculosis*: purification by countercurrent distribution and T-cell stimulation. *Microbios* **106**: 55-67.

Goren M.B. (1979). Mycobacterial lipids: chemistry and biologic activities. In, Youms G. (ed) *Tuberculosis*, WB Sanders Company. Philadelphia. 63-193.

Gotoh K., Mitsuyama M., Imaizumi S., Kawamura I., and Yano I. (1991). Mycolic acids-containing glycolipid as possible virulence factor of *Rhodococcus equi* for mice. *Microbiol Immunol.* **35**: 75-185.

Grange J.M. (1996). The biology of the genus Mycobacterium. *Soc Appl Bacteriol Symp Ser.* **25**: 1S-9S.

Grange J.M. (1980). Recent European research activities in mycobacteriology. *Tubercle.* **61**: 259-68.

Grange J.M. (1984). The humoral immune response in tuberculosis: its nature, biological role and diagnostic usefulness. *Adv Tuberc Res.* **21**: 1-78.

Gresser I. and Naficy K. (1964). Recovery of an interferon-like substance from cerebrospinal fluid. *Proc Soc Exp Biol Med.* **117**: 285-289.

Grosset J. (1995). The challenge of tuberculosis: statements on global control and prevention. Treatment in developed countries. *Lancet.* **346**: 810-2.

Guillemard E., Geniteau-Legendre M., Kergot R., Lemaire G., Gessani S., Labarre C., and Quero A.M. (1998). Simultaneous production of IFN-gamma, IFN-alpha/beta and nitric oxide in peritoneal macrophages from TDM-treated mice. *J Biol Regul Homeost Agents.* **12**: 106-11.

Hamblin A.S., (1993) Cytokines one by one. In: Male D. (ed), *Cytokines and Cytokine Receptors* 2nd edition, Oxford University Press., NY. 21-44.

Harding S.M. and Bailey W.C., (1994). Chemotherapy of tuberculosis. In, David Schlossberg (ed) *Tuberculosis* 3rd edition. Springer-Verlag New York. 69-74.

Hasegawa T., Okuda M., Makino M., Hiromatsu K., Nomoto K., and Yoshikai Y. (1995). Hot water extracts of *Chlorella vulgaris* reduce opportunistic infection with *Listeria monocytogenes* in C57BL/6 mice infected with LP-BM5 murine leukemia viruses. *Int J Immunopharmacol.* **17**: 505-12.

Helson L., Green S., Carswell E., and Old L.J. (1975). Effect of tumour necrosis factor on cultured human melanoma cells. *Nature.* **258**: 731-2.

Henderson R.A., Watkins S.C., and Flynn J.L. (1997). Activation of human dendritic cells following infection with *Mycobacterium tuberculosis*. *J Immunol.* **159**: 635-43.

Hernandez-Pando R. and Rook G.A.W. (1994). The role of TNF- α in T cell mediated inflammation depends on the Th1/Th2 cytokine balance. *Immunology* **82**: 591-595.

Hernandez-Pando R., Pavon L., Orozco E.H., Rangel J., Rook G.A. (2000). Interactions between hormone-mediated and vaccine-mediated immunotherapy for pulmonary tuberculosis in BALB/c mice. *Immunology* **100**: 391-8.

Heym B., Honore N., Truffot-Pernot C., Banerjee A., Schurra C., Jacobs W.R. Jr, van Embden J.D., Grosset J.H., and Cole S.T. (1994). Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. *Lancet* **344**: 293-8.

Hienzel F.P., Scheonhaut D.S., Rerko R.M., Rosser L.E., and Gatey M.K., (1993) Recombinant interleukin 12 cures mice infected with *Leishmania major*. *J Exp Med.* **177**: 1505-9.

Higuchi R., Dollinger G., Walsh P.S., and Griffith, R. (1992). Simultaneous amplification and detection of specific DNA sequences. *Biotechnology* **10**: 413-7.

Higuchi R., Fockler C., Dollinger, G., and Watson R. (1993). Kinetic PCR analysis: Real-time monitoring of DNA amplification reactions. *Biotechnology* **11**: 1026-30.

Himathongkham S., Halpin N.S., Li J., Stout M.W., Miller C.J., and Luciw PA. (2000). Simian-human immunodeficiency virus containing a human immunodeficiency virus type 1 subtype-E envelope gene: persistent infection, CD4(+) T-cell depletion, and mucosal membrane transmission in macaques. *J Virol.* **74**: 7851-60.

Hiromatsu K., Nishimura H., Kimura K., Aoki Y., Usami J., Kobayashi N., Makino M., and Yoshikai Y. (1996). Th0-like CD4+ T cells protect mice with murine retrovirus-induced immunodeficiency syndrome (MAIDS) against co-infection with *Listeria monocytogenes*. *Immunology.* **89**: 532-8.

Holland P.M., Abramson R.D., Watson R., and Gelfand D.H. (1991). Detection of specific polymerase chain reaction product by utilizing the 5'---3' exonuclease activity of *Thermus aquaticus* DNA polymerase. *Proc Natl Acad Sci USA*. **88**: 7276-80.

Hoover E.A., McCullough C.B., Griesemer R.A. (1972). Intranasal transmission of feline leukemia. *J Natl Cancer Inst*. **48**: 973-83.

Horwitz M.A., Lee B.W., Billon B.J., and Harth G., (1998). Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of *Mycobacterium tuberculosis*. *Proc Natl Acad Sci USA*. **92**: 1530-1534.

Hsieh C., Macatonia S.E., Troipp C.S., Wolf S.F., O'Garra A., and Murphy K.M. (1993). Development of Th1 CD4⁺ T cells through IL-12 produced by *Listeria*-induced macrophages. *Science* **260**: 547-9.

Huang S., Hendriks W., Althage A., Hemmi S., Bluethmann H., Kamijo R., Vilcek J., Zinkernagel R.M., and Aguet M. (1993). Immune response in mice that lack the interferon-gamma receptor. *Science* **259**: 1742-5.

Huebner R.E. (1996). BCG vaccination in the control of tuberculosis. *Curr Top Microbiol Immunol*. **215**: 263-82.

Janeway C.A. and Travers P. (1996). *Immunobiology: The immune system in health and disease*. Blackwell Scientific Publications, Oxford. Chapter 7.

Jolicoeur P. (1991). Murine acquired immunodeficiency syndrome (MAIDS): an animal model to study the AIDS pathogenesis. *FASEB J*. **5**: 2398-405.

Jordan J.A. (2000). Real-time detection of PCR products and microbiology. *New technologies for life sciences: A Trends Guide* **6**: 61-6.

Kaplan G., Nathan C.F, Gandhi R., Horwitz M.A., Levis W.R., and Cohn Z.A. (1986). Effect of recombinant interferon-gamma on hydrogen peroxide-releasing capacity of monocyte-derived macrophages from patients with lepromatous leprosy. *J Immunol.* **137**: 983-7.

Kappes D. and Strominger J.L. (1988). Human class II major histocompatibility complex genes and proteins. *Annu Rev Biochem.* **57**: 991-996.

Kasinrerk W., Baumruker T., Majdic O., Knapp W., and Stockinger H. (1993). CD1 molecule expression on human monocytes induced by granulocyte-macrophage colony-stimulating factor. *J Immunol.* **150**: 579-84.

Kato M. (1973). Effect of anti-cord factor antibody on experimental tuberculosis in mice. *Infect Immun.* **7**: 14-21.

Kaufmann S.H. and Andersen P. (1998). Immunity to mycobacteria with emphasis on tuberculosis: implications for rational design of an effective tuberculosis vaccine. *Chem Immunol.* **70**: 21-59.

Kaufmann S.H., and van Embden J.D. (1993). Tuberculosis: a neglected disease strikes back. *Trends Microbiol.* **1**: 2-5.

Kaufmann S.H.E. and De Libero G. (1988). Cytolytic T cells in *M. tuberculosis* infections. In Mauro Bendinelli and Herman Friedman (Eds) *Mycobacterium tuberculosis: interaction with the immune system*, Plenum Press, New York. 151-170.

Kawano T., Cui J, Koezuka Y., Toura I., Kaneko Y., Sato H., Kondo E., Harada M., Koseki H., Nakayama T., Tanaka Y., and Taniguchi M. (1998). Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. *Proc Natl Acad Sci U S A.* **95**:5690-3.

Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., Ueno H., Nakagawa R., Sato H., Kondo E., Koseki H., and Taniguchi M. (1997). CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. *Science* **278**: 1626-9.

Kemp K., Hviid L., Kharazmi A., and Kemp M. (1997). Interferon-gamma production by human T cells and natural killer cells in vitro in response to antigens from the two intracellular pathogens *Mycobacterium tuberculosis* and *Leishmania major*. *Scand J Immunol.* **46**: 495-9.

Kim W.K., Tang Y., Kenny J.J., Longo D.L., and Morse H.C. 3rd. (1994). In murine AIDS, B cells are early targets of defective virus and are required for efficient infection and expression of defective virus in T cells and macrophages. *J Virol.* **68**: 6767-9.

King T.P. and Craig L.C., (1962). Countercurrent Distribution., In: Click D. (Ed), *Methods of Biological Analysis*, Inter-Science Publishers, NY, London. Vol.X: 201-288

Klein SJ, Simard C, Jolicoeur P. (1998). Establishment of MAIDS-defective virus-infected B cell lines and their characterization. *Virology* **244**:283-93.

Klinman N.R., Ales-Martinez J.E., and Scott D.W. (1992). The parameters of B-cell inactivation in transgenic mice vs classical model studies. *Res Immunol.* **143**: 279-85.

Kobayashi, M, L Fitz, M Ryan *et al.* 1989. Identification and purification of natural killer cell stimulatory factor (NKSF) a cytokine with multiple biologic effects on human lymphocytes. *J Exp Med.* **170**: 827-845.

Koch S, Muralidhar G, Swain SL. (1994). Both naive and memory CD4 T cell subsets become anergic during MAIDS and each subset can sustain disease. *J Immunol.* **152**: 5548-56.

Kohno K., Holan V., Matsuda S., Kurimoto M., and Minowada J. (1992). The immunomodulatory role of IFN-alpha or maltose-stabilized IFN-alpha on T-cell activation. *Lymphokine Cytokine Res.* **11**: 221-7.

Kohno K., Kataoka J., Ohtsuki T., Suemoto Y., Okamoto I., Usui M., Ikeda M., and Kurimoto M. (1997). IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. *J Immunol.* **158**: 1541-50.

Kubica G.P., Dye E., Cohn M.L., and Middlebrook G. (1963) Sputum digestion and decontamination with *N*-acetyl-L-cysteine-sodium hydroxide for culture of mycobacteria. *Am Rev Resp Dis.* **87**: 775-779.

Ladel C.H., Bum C., Dreher A., Reifenberg K., Kopf M., and Kaufmann S.H.E., (1997). Lethal tuberculosis in interleukin-6-deficient mutant mice. *Infect Immun.* **65**: 4843-4849
Ladel C.H., Szalay G., Riedel D., and Kaufmann S.H.E., (1997). Interleukin-12 secretion by *Mycobacterium tuberculosis*-infected macrophages. *Infect Immun.* **65**: 1936-1939.

Lee JS, Giese NA, Elkins KL, Yetter RA, Holmes KL, Hartley JW, and Morse HC 3rd. (1995). Effects of exogenous, nonleukemogenic, ecotropic murine leukemia virus infections on the immune systems of adult C57BL/6 mice. *J Virol.* **69**:4182-8.

Leenen .P.J., Canono B.P., Drevets D.A., Voerman J.S., Campbell P.A.. (1994). TNF-alpha and IFN-gamma stimulate a macrophage precursor cell line to kill *Listeria monocytogenes* in a nitric oxide-independent manner. *J Immunol.* **153**: 5141-7.

Lenaerts A.M., Chase S.E., and Cynamon M.H. (2000). Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model. *Antimicrob Agents Chemother.* **44**: 3167-8.

Lenaerts A.M., Chase S.E., Chmielewski A.J., and Cynamon M.H. (1999). Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. *Antimicrob Agents Chemother.* **43**: 2356-60.

Levy J.A., Hoffman A.D., Kramer S.M., Landis J.A., Shimabukuro J.M., Oshiro L.S. (1984). Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. *Science* **225**: 840-2.

Liakopoulou A. (1989). Effects of rifampin treatment on contact sensitivity reactions to oxazolone in Balb/C mice. *Immunopharmacol Immunotoxicol.* **11**: 179-92.

Liang B, Wang JY, Watson RR. (1996). Murine AIDS, a key to understanding retrovirus-induced immunodeficiency. *Viral Immunol.* **9**:225-39.

Lombard D. C. (2002). The effect of mycobacterial mycolic acids on the cytokine profile of the immune response in murine tuberculosis. M.Sc. Thesis, Department of Biochemistry, Faculty of Natural and Agricultural Sciences, University of Pretoria

Londei M., Clayton J., and Feldman M., (1991). T cells and cytokines. In, Balkwill F.R. (ed), *Cytokines, A Practical Approach*, Oxford University Press., Oxford, NY, Tokyo. 151-169

Londei M., Savill C., Verhoef A., Brennan F., Leech Z.A., Duance V., Maini R.N., and Feldman M., (1989) Persistence of collagen type II specific T cell clones in the synovial membrane of a patient with RA. *Proc Natl Acad Sci USA* **86**: 636-640.

Lordi G.M and Reichman L.B. (1999). In, David Schlossberg (ed) *Tuberculosis* 4th edition. Springer-Verlag New York. 65-70.

Lowrie DB, Tascon RE, Bonato VL, Lima VM, Faccioli LH, Stavropoulos E, Colston MJ, Hewinson RG, Moelling K, Silva CL. (1999). Therapy of tuberculosis in mice by DNA vaccination. *Nature* **400**: 269-71.

Ma Y., Seiler K.P., Tai K.F., Yang L.M., Woods M., and Weis J.J., (1994). Outer surface lipoproteins of *Borrelia burgdorferi* stimulate nitric oxide production by the cytokine-inducible pathway. *Infect Immun.* **62**: 3663-3671.

Maher D, Hausler HP, Raviglione MC, Kaleeba N, Aisu T, Fourie B, Nunn P. (1997). Tuberculosis care in community care organizations in sub-Saharan Africa: practice and potential. *Int J Tuberc Lung Dis.* **1**:276-83.

Makino M, Chattopadhyay SK, Hartley JW, Morse HC 3rd. (1992). Analysis of role of CD8+ T cells in resistance to murine AIDS in A/J mice. *J Immunol.* **149**:1702-6.

Malaviya R., Ikeda T., Ross E., Abraham S.N. (1996). Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. *Nature* **381**:77-80.

Maniatis, T. (1982). *Molecular Cloning. A Laboratory Manual.* Cold Spring Laboratory Publications, New York.

Mendez-Samperio P., Gonzalez-Garcia L., Pineda-Fragoso P.R., Ramos-Sanchez E. Pedrazzini T. and Lois J., (1986). Functional analysis invitro and in vivo of *M. bovis* BCG specific T cell clones. *J Immunol.* **152**: 1828-31.

Mendez-Samperio P., Gonzalez-Garcia L., Pineda-Fragoso PR, Ramos-Sanchez E. (1995). Specificity of T cells in human resistance to *Mycobacterium tuberculosis* infection. *Cell Immunol.* **162**: 194-201.

Micallef M.J., Ohtsuki T., Kohno K., Tanabe F., Ushio S., Namba M., Tanimoto T., Torigoe K., Fujii M., Ikeda M., Fukuda S., and Kurimoto M. (1996). Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. *Eur J Immunol.* **26**: 1647-51.

Minnikin DE, Minnikin SM, Parlett JH, Goodfellow M, and Magnusson M. (1984). Mycolic acid patterns of some species of *Mycobacterium*. *Arch Microbiol.* **139**: 225-31.

Minnikin, D.E. and Goodfellow M. (1980). In: *Microbiological Classification and Identification*. Goodfellow M and Board R G (Eds). London: Academic press. 189-256

Minnikin, D.E., (1982). Lipids: complex lipids, their chemistry, biosynthesis and roles. In: Ratledge C. and Stanford J.L., (Eds) *The biology of mycobacteria*. London: Academic press. 95-184.

Mitchison DA. (1969). What is drug resistance? *Tubercle* **50**: 44-7.

Mitchison DA. (1998). How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. *Int J Tuberc Lung Dis.* **2**:10-5.

Morawetz R.A., Doherty T.M., Giese N.A, Hartley J.W., Muller W., Kuhn R., Rajewsky K., Coffman R., and Morse H.C. 3rd.(1994). Resistance to murine acquired immunodeficiency syndrome (MAIDS). *Science* **265**: 264-6.

Morawetz R.A., Gabriele L., Rizzo L.V., Noben-Trauth N., Kuhn R., Rajewsky K., Muller W., Doherty T.M., Finkelman F., Coffman R.L., and Morse H.C. 3rd. (1996). Interleukin (IL)-4-independent immunoglobulin class switch to immunoglobulin (Ig)E in the mouse. *J Exp Med.* **184**: 1651-61.

Morse H.C. 3rd, Chattopadhyay S.K., Makino M., Fredrickson T.N., Hugin A.W., and Hartley J.W. (1992). Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS. *AIDS*. **6**: 607-21.

Morse H.C. 3rd, Giese N, Morawetz R., Tang Y., Gazzinelli R., Kim W.K., Chattopadhyay S., and Hartley J.W. (1995). Cells and cytokines in the pathogenesis of MAIDS, a retrovirus-induced immunodeficiency syndrome of mice. *Springer Semin Immunopathol*. **17**: 231-45.

Mosier D.E. (1996). Small animal models for acquired immune deficiency syndrome (AIDS) research. *Lab Anim Sci*. **46**: 257-65.

Mosier D.E., Yetter R.A., and Morse H.C. 3rd. (1987). Functional T lymphocytes are required for a murine retrovirus-induced immunodeficiency disease (MAIDS). *J Exp Med*. **165**: 1737-42.

Mosmann T.R. and Coffman R.L. (1989). Heterogeneity of cytokine secretion patterns and functions of helper T cells. *Adv Immunol*. **46**: 111-47.

Moura A.C. and Mariano M. (1996). Lipids from *Mycobacterium leprae* cell wall are endowed with an anti-inflammatory property and inhibit macrophage function in vivo. *Immunology* **89**: 613-8.

Moura A.C., Modolell M., and Mariano M. (1997). Down-regulatory effect of *Mycobacterium leprae* cell wall lipids on phagocytosis, oxidative respiratory burst and tumour cell killing by mouse bone marrow derived macrophages. *Scand J Immunol*. **46**: 500-5.

Muralidhar G, Koch S, Broome HE, Swain SL. (1996). TCR triggering of anergic CD4 T cells in murine AIDS induces apoptosis rather than cytokine synthesis and proliferation. *J Immunol*. **157**: 625-35.

Muralidhar G, Koch S, Haas M, Swain SL. (1992). CD4 T cells in murine acquired immunodeficiency syndrome: polyclonal progression to anergy. *J Exp Med.* **175**: 1589-99.

Murch S.H. (1995). Cellular mediators of lung damage. *Brit J Intensive Care* **15** :27

Murray H.W. (1994). Interferon-gamma and host antimicrobial defense: current and future clinical applications. *Am J Med.* **97**: 459-67.

Myszka D.G. and Rich R.L. (2000). Implementing surface plasmon resonance biosensors in drug discovery. *Pharm Sci Technol Today.* **3**: 310-317.

Nathan C. and Yoshida R. (1988). Cytokines: interferon-gamma, in Gallin J.I, Goldstein I.M., Snyderman R. (Eds). *Inflammation: Basic principles and Clinical Correlates*. Raven press, New York 229-251.

Nathan C.F. (1983). Environmental control of tuberculosis. *Med Clin North Am.* **77**: 1315-34.

Nathan C.F. (1987). Neutrophil activation on biological surfaces. Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. *J Clin Invest.* **80**: 1550-60.

Nel E.E., Kleeberg H.H. and Gatner E.M.S. (1980). *Laboratory Manual of tuberculosis methods*. Second Ed. Tuberculosis Research Institute, Pretoria.

Neyer L.E, Grunig G., Fort M., Remington J.S., Rennick D., and Hunter C.A. (1997). Role of interleukin-10 in regulation of T-cell-dependent and T-cell-independent mechanisms of resistance to *Toxoplasma gondii*. *Infect Immun.* **65**: 1675-82.

Oakley OR, Hughes NK, Birch NJ, Winther ML, Horrobin DF, Gallicchio VS. (1998). The effects of lithium gamma-linolenic acid in reversing LPBM5 MuLV induced suppression of hematopoietic progenitor cells in vitro. *Rom J Physiol.* **35**:13-24.

Ogasawara K., Takeda K., Hashimoto W., Satoh M., Okuyama R., Yanai N., Obinata M., Kumagai K., Takada H., Hiraide H., and Seki S. (1998). Involvement of NK1+ T cells and their IFN-gamma production in the generalized Shwartzman reaction. *J Immunol.* **160**: 3522-7.

Olshevsky U., Helseth E., Furman C., Li J., Haseltine W. and Sodroski J. (1990). Identification of individual human immunodeficiency virus type 1 gp 120 amino acids important for CD4 receptor binding. *J Virol.* **64**: 5701-7.

Orbach-Arbouys S. Tenu J.P., and Petit J.F. (1983). Enhancement of *in vitro* and *in vivo* antitumour activity by cord factor administered suspended in saline. *Int J Allergy Applied Immun.* **71**: 67-73.

Orme IM, Furney SK, Roberts AD. (1992). Dissemination of enteric Mycobacterium avium infections in mice rendered immunodeficient by thymectomy and CD4 depletion or by prior infection with murine AIDS retroviruses. *Infect Immun.* **60**: 4747-53.

Orme IM. (1987). Aging and immunity to tuberculosis: increased susceptibility of old mice reflects a decreased capacity to generate mediator T lymphocytes. *J Immunol.* **138**: 4414-8.

Orme IM. (1996). Immune responses in animal models. *Curr Top Microbiol Immunol.* **215**: 181-96.

Orme, I M. 1993. Immunity to mycobacteria. *Curr Opin Immunol*, **5**, 497-502.

Oswald IP, Dozois CM, Petit JF, and Lemaire G. (1997). Interleukin-12 synthesis is a required step in trehalose dimycolate-induced activation of mouse peritoneal macrophages. *Infect Immun.* **65**:1364-9.

Palamara A.T., Garaci E., Rotilio G., Ciriolo M.R., Casabianca A., Fraternali A., Rossi L. Schiavano G.F, Chiarantini L., and Magnani M. (1996). Inhibition of murine AIDS by reduced glutathione. *AIDS Res Hum Retroviruses* **12**: 1373-81.

Pan J, Fujiwara N, Oka S, Maekura R, Ogura T, and Yano I. (1999). Anti-cord factor (trehalose 6,6'dimycolate) IgG antibody in tuberculosis patients recognizes mycolic acid subclasses. *Microbiol Immunol.* **43**: 863-9.

Pathak S.S. (1995). Antibody affinity and affinity distributions: Determinations in ELISA and Biosensor. Ph.D thesis Department of Immunology, Erasmus University Rotterdam, The Netherlands.

Peacock C.D, Olver S.D., and Price P. (1997). Effect of a retroviral immunodeficiency syndrome on murine cytomegalovirus-induced hepatitis. *Am J Pathol.* **150**: 1089-100.

Peacock C.D. and Price P. (1999). The role of IL-12 in the control of MCMV is fundamentally different in mice with a retroviral immunodeficiency syndrome (MAIDS). *Immunol Cell Biol.* **77**: 131-8.

Pece S., Giuliani G., Fumarola D., Mastroianni C.M., Lichtner M., Vullo V., Antonaci S., and Jirillo E. (1997). In vitro production of tumor necrosis factor-alpha, interleukin-6 and interleukin-8 from normal human peripheral blood mononuclear cells stimulated by *Rhodococcus equi*. *Vet Microbiol.* **56**:277-85.

Pedrazzini T. and Louis J.A. (1996). Functional analysis in vitro and in vivo of *Mycobacterium bovis* strain BCG-specific T cell clones. *J Immunol.* **136**:1828-34.

Perussia B., Chan S.H., D'Andrea A., Tsuji K., Santoli D., Pospisil M., Young D., Wolf S.F., and Trinchieri G. (1992). Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells. *J Immunol.* **149**: 3495-502.

Petit J-F. and Lederer E., (1984). The structure of mycobacterial cell wall. In: Kubica G.P. and Wayne L.G. (Eds), *The mycobacteria, a source book*, Marcel Dekker Inc. NY., 301-314.

Pieters J. and Gatfield J. (2002). Hijacking the host: survival of pathogenic mycobacteria inside macrophages. *Trends Microbiol.* **10**: 142-6.

Pitchenik A.E., Guffee J., Stein-Streilein J. (1987). Lung natural killer and interleukin-2 activity in lung cancer. A pulmonary compartment of augmented natural killer activity occurs in patients with bronchogenic carcinoma. *Am Rev Respir Dis.* **136**:1327-32.

Pitzalis C., Kingsley G., Murphy J., and Panayi G., 1987. Abnormal distribution of the helper inducer and suppressor-inducer T-lymphocyte subsets in the rheumatoid joint. *Clin Immunol Immunopathol* **45**: 252-258.

Porcelli S. Morita C.T. and Brenner M.B. (1992). CD1b restricts the response of human CD4⁺ T lymphocytes to a microbial antigen. *Nature.* **360**: 593-597.

Portillo G., Turner M, Chantry D., Feldmann M., 1989. Effect of cytokines on HLA-DR and IL-1 production by monocytic tumour, THP-1. *Immunology* **66**(2): 170-175.

Portmann A.J., Levison S.A., and Dandliker W.B. (1971). Anti-fluorescein antibody of high affinity and restricted heterogeneity as characterized by fluorescence polarization and quenching equilibrium techniques. *Biochem Biophys Res Commun.* **43**: 207-12.

Portnoi D., Stall A.M., Schwartz D., Merigan T.C., Herzenberg L.A., and Basham T. (1990). Zidovudine (azido dideoxythymidine) inhibits characteristic early alterations of lymphoid cell populations in retrovirus-induced murine AIDS. *J Immunol.* **144**: 1705-10.

Pretorius A., (1999). Humoral and Cellular immunogenicity of mycobacterial mycolic acids in tuberculosis. M.Sc. Thesis, Department of Biochemistry, Faculty of Biological and Agricultural Sciences, University of Pretoria.

Raffel S., Arnaud L.E., Dukes C.D., and Huang J.S. (1949). The role of wax of tubercle bacillus in establishing delayed hypersensitivity. *J Exp Med.* **90**: 53-71.

Raines E.W., Dower S.K., and Ross R. (1989) Interluken 1 mitogenic activity for fibroblast and smooth muscles is due to PDGF AA. *Science* **243**: 393-397.

Ravn P., Boesen H., Pedersen B.K., and Andersen P., (1997). Human T cell repressors induced by vaccination with *M.bovis* Bacillus Calmette Guerin. *J Immunol.* **58**: 1941-1955.

Reichman L.B. (1997). Tuberculosis elimination what's to stop us? *Int J Tuberc Lung Dis.* **1**: 3-11.

Reiner S.L., Zheng S., Corry D.B. and Locksley R.M. (1994). Constructing polycompetitor cDNA for quantitative PCR. *J Immunol Methods.* **175**: 275-280.

Rhoades E.R., Cooper A.M., and Orme I.M. (1995). Chemokine response in mice infected with *Mycobacterium tuberculosis*. *Infect Immun.* **63**: 3871-7.

Ribi E., Larson C., Wicht W., List R., and Goode G., (1966). Effective nonliving vaccine against experimental tuberculosis in mice. *J Bacterial.* **91**: 975-983.

Riedel D.D. and Kaufmann S.H. (2000). Differential tolerance induction by lipoarabinomannan and lipopolysaccharide in human macrophages. *Microbes Infect.* **2**: 463-71.

Roberts G.D., Bottger E.C., and Stockman L. (1996). Methods for the rapid identification of mycobacterial species. *Clin Lab Med.* **16**: 603-15.

Roitt I., Brostoff J., and Male D. (1993). *Immunology*, 3rd edition. Mosby. Boston and London.

Rojas A., Caveda L., Romay C., Lopez E., Valdes S., Padron J., Glaria L., Martinez O., and Delgado R. (1996). Effect of advanced glycosylation end products on the induction of nitric oxide synthase in murine macrophages. *Biochem Biophys Res Commun.* **225**: 358-62.

Rook G.A., and Hernandez-Pando R. (1994). T cell helper types and endocrines in the regulation of tissue-damaging mechanisms in tuberculosis. *Immunobiology* **191**: 478-92.

Rook G.A.W., and Hernandez-Pando R. (1996) The pathogenesis of tuberculosis. *Annu Rev Microbiol.* **50**: 259-284.

Rook G.A.W., and Hernandez-Pando R., (1997). Pathogenetic role, in human and murine tuberculosis, of changes in the peripheral metabolism of glucocorticoids and antiglucocorticoids. *Psychoendocrinology* **22**(suppl 1):s109-s113.

Rook, G.A.W., Taverne J., Leveton C. and Steele J. (1987). The role of gamma interferon, vitamin D3 metabolites and tumor necrosis factor in the pathogenesis of tuberculosis. *Immunology* **67**: 229-243.

Sato K., Akaki T., and Tomioka H. (1998). Differential potentiation of anti-mycobacterial activity and reactive nitrogen intermediate-producing ability of murine peritoneal macrophages activated by interferon-gamma (IFN- γ) and tumour necrosis factor-alpha (TNF- α). *Clin Exp Immunol.* **112**: 63-68.

Saunders B.M. and Cheers C. (1995). Inflammatory response following intranasal infection with *Mycobacterium avium* complex: role of T-cell subsets and gamma interferon. *Infect Immun.* **63**: 2282-7.

Scharer L.L. and McAdam J.M. (1995). Treatment of tuberculosis infection and disease. In: *Tuberculosis and Aids: The relationship between mycobacterium TB and the HIV type 1*. Springer Publishing Co. New York. 89-132.

Scharton-Kersten T., Caspar P., Sher A., and Denkers E.Y. (1996). *Toxoplasma gondii*: evidence for interleukin-12-dependent and-independent pathways of interferon-gamma production induced by an attenuated parasite strain. *Exp Parasitol.* **84**: 102-14.

Scharton-Kersten T., Nakajima H., Yap G., Sher A., and Leonard W.J. (1998). Infection of mice lacking the common cytokine receptor gamma-chain (gamma(c)) reveals an unexpected role for CD4+ T lymphocytes in early IFN-gamma-dependent resistance to *Toxoplasma gondii*. *J Immunol.* **160**: 2565-9. yn P.A., Tra

Schauf V., Rom W.N., Smith K.A., Sampaio E.P., Me montana J.M., Cohn Z.A., and Kaplan G. (1993). Cytokine gene activation and modified responsiveness to interleukin-2 in the blood of tuberculosis patients. *J Infect Dis.* **168**: 1056-9.

Schebesch C., Kodelja V., Muller C., Hakij N., Bisson S., Orfanos C.E., Goerdts S. (1997). Alternatively activated macrophages actively inhibit proliferation of peripheral blood lymphocytes and CD4+ T cells in vitro. *Immunology* **92**: 478-86.

Scott P., (1993). Initiation cytokine for cell-mediated immunity. *Science* **260**: 496-497.

Schleicher G K, Feldman C, Verschoor J A, Vermaak Y. Prevalence of anti- mycolic acid antibodies in pulmonary tuberculosis patients co-infected with HIV. *Clin Chem Lab Med* 2002: *in press*.

Selwyn P.A., Hartel D., Lewis V.A., Schoenbaum E.E., Vermund .SH., Klein R.S., Walker A.T., Friedland G.H. (1989). A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. *N Engl J Med*. **320**: 545-50.

Shafer R.W., Edlin B.R. (1996). Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade. *Clin Infect Dis*. **22**: 683-704.

Sher A. and Coffman R.L. (1992). Regulation of immunity to parasites by T cells and T cell-derived cytokines. *Annu Rev Immunol*. **10**: 385-409.

Shinners D. and Yeager H. (1999). Clinical syndromes and diagnosis. In: David Schlossberg (ed) *Tuberculosis* 4th edition. Springer-Verlag New York. 341-350.

Sieling P.A., Abrams J.S., Yamamura M., Salgame P., Bloom B.R., Rea T.H., and Modlin R.L. (1993). Immunosuppressive roles for IL-10 and IL-4 in human infection. *In vitro* modulation of T cell responses in leprosy. *J Immunol*. **150**::5501-10.

Sieling P.A., Wang X-H., Gateley K., Oliveros J.L, McHugh T., Barnes P.F., Wolf S.F., Golkar L., Yamamura M., Yogi Y., Uyemura K., Rea T.H., and Modlin R., (1994). IL-12 regulates T helper type 1 cytokine responses in human infectious disease. *J Immunol*. **153**: 3639-3647

Sieling P.A., Chatterjee D., Porcelli S.A., Prigozy T.I., Mazzaccaro R.J., Soriano T., Bloom B.R., Brenner M.B., Kronenberg M., Brennan P.J. (1995). CD1-restricted T cell recognition of microbial lipoglycan antigens. *Science*. **269**: 227-30.

Siko D.G.R. (1999). The effects of mycobacterial mycolic acids on rodent tuberculosis and adjuvant arthritis. M.Sc. Thesis, Department of Biochemistry, Faculty of Biological and Agricultural Sciences, University of Pretoria.

Skinner M.A., Yuan S., Prestidge R., Chuk D., Watson J.D., and Tan P.L. (1997). Immunization with heat-killed *Mycobacterium vaccae* stimulates CD8+ cytotoxic T cells specific for macrophages infected with *Mycobacterium tuberculosis*. *Infect Immun.* **65**: 4525-30.

Small P.M., Slater R.W., and Hopewell P.C., (1993). Exogenous reinfection with multidrug-resistant *Mycobacterium tuberculosis* in patients with advanced HIV infection. *N Engl J Med.* **328**: 1137-1144.

Snijders A., Hilkens C.M., van der Pouw Kraan T.C., Engel M., Aarden .LA., and Kapsenberg M.L. (1996). Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit. *J Immunol.* **156**: 1207-12.

Spargo B.J., Crowe L.M., Ionedo T., Beaman B.L., and Crowe J.H. (1991). Cord factor (alpha,alpha-trehalose 6,6'-dimycolate) inhibits fusion between phospholipid vesicles. *Proc Natl Acad Sci USA.* **88**:737-40.

Stead W.W., and Dutt A.K., (1988). The changing faces of clinical tuberculosis. In Mauro Bendinelli and Herman Friedman (Eds) *Mycobacterium tuberculosis: interaction with the immune system*, Plenum Press, New York. 151-170.

Stead W.W, and DuttA.K., (1999). Epidemiology and host factors. In: David Schlossberg (ed) *Tuberculosis* 4th edition. . Springer-Verlag New York. 1-15

Stein M., Keshav S., Harris N., and Gordon S. (1992). Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. *J Exp Med.* **176**: 287-92.

Stern A.S., Polski F.J., Hulmes J.D., Pan Y.C.E., Quinn P.M., Wolitzky A.G., Familletti P.C, Strembo D.L., Truitt T., Chizzonite R., and Gately M.K., (1990). Purification and partial characterization of cytotoxic lymphocyte maturing factor from human B-lymphoblastoid cells. *Proc Natl Acad Sci USA.* **87**: 6805-6810.

Steyn L., (1996). Tuberculosis. At: www.uct.ac.za/mmi/lsteyn

Stoltz A.C. (2002). Immunological properties of mycolic acids, the major lipid cell wall component of mycobacterium tuberculosis. Ph.D. Thesis, Department of Physiology, Faculty of Medicine, University of Pretoria.

Sturgill-Koszycki S., Schlesinger P.H., Chakraborty P., Haddix P.L., and Collins H.L., (1994). Lack of acidification in *Mycobacterium* phagosomes produced by exclusion of the vesicular protein ATPase. *Science* **263**: 678-681.

Sugita M., Moody D.B., Jackman R.M., Grant E.P., Rosat J.P., Behar S.M., Peters P.J., Porcelli S.A., Brenner M.B., (1998). Molecule of the month: CD1-a new paradigm for antigen presentation and T cell activation. *Clin Immun Immunopath.* **87**: 8-14.

Sypek J.P., Chung C.L., Mayor S.E.H., Subramanyan J.M., Goldman S.J., Sieburth D.S., Wolf S.F., and Schaub R.G., (1993). Interluyken 12 initiates a protective T helper type 1 immune response. *J Exp Med.* **177**: 1797-1802.

Szalay G, Zugel U, Ladel CH, Kaufmann SH. (1999). Participation of group 2 CD1 molecules in the control of murine tuberculosis. *Microbes Infect.* **1**: 1153-7.

Takayama K., Wang L., and David H.L.,(1972). Effect of isoniazid on in vitro mycolic acids synthesis, cell growth and viability of *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother.* **2**: 29-35

Tanaka Y., Morita C.T., Tanaka Y., Nieves E., Brenner M.B., Bloom B.R. (1995). Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. *Nature* **375**:155-8.

Taniguchi A., Kohsaka H., and Carson D.A., (1993). Competitive RT-PCR ELISA a rapid, sensitive and non-radioactive method to quantitate cytokine mRNA. *J Immunol Methods* **169**: 101-109

Tascon R.E., Stavropoulos E., Lukacs K.V., and Colston M.J. (1998). Protection against *Mycobacterium tuberculosis* infection by CD8+ T cells requires the production of gamma interferon. *Infect Immun.* **66**: 830-4.

Ten Bokum A.M.C. , Siko D.G.R. , Kirberger R.M. , Van Wyngaardt S. , Venter J.D. , and Verschoor J.A. (2002). Mycobacterially induced arthritis: effect of mycobacterial mycolic acids (Submitted).

Tentori L., Graziani G., Porcelli S.A., Sugita M., Brenner M.B., Madio R., Bonmassar E., Guiliani A., and Aquino A., (1998). Rifampin increases cytokine induced expression of CD1b molecules in human peripheral blood monocytes. *Antimicrob Agents Chemother.* **42**: 550-554.

Thole J.E.R., Hindersson P., De Bruyn J., Cremers F., Van der Zee J., De Cock H., Tommassen J., Van Eden W., and Van Embden J.D.A. (1988). Antigenic relatedness of a strongly immunogenic 65 kD mycobacterial protein antigen with a similarly sized ubiquitous bacterial common antigen. *Microbiol Pathog.* **4**: 71-83.

Thole J.E.R., Keulen W.J., Koki A.H.J., Bewald L.G., Tiesjema R.H., and Van Embden J.D.A., (1987). Characterization, sequence determination , and immunogenicity of a 64 KD protein of *M. bovis* BCG expression in *E. coli* K12. *Infect Immun.* **55**: 1466-1475.

Thomssen H., Ivanyi J., Espitia C., Arya A., and Londei M. (1995). Human CD4-CD8-alpha beta + T-cell receptor T cells recognize different mycobacteria strains in the context of CD1b. *Immunology* **85**: 33-40.

Thomssen H., Kahan M., and Londei M. (1995). Differential effects of interleukin-10 on the expression of HLA class II and CD1 molecules induced by granulocyte/macrophage colony-stimulating factor/interleukin-4. *Eur J Immunol.* **25**: 2465-70.

Toossi Z. (2002). The multiple faces of the immune response to *Mycobacterium tuberculosis*. *Trends Microbiol.* **10**: 359-60.

Toossi Z., Hirsch C.S., Hamilton B.D., Knuth C.K., Friedlander M.A., and Rich E.A. (1996). Decreased production of TGF-beta 1 by human alveolar macrophages compared with blood monocytes. *J Immunol.* **156**: 3461-8.

Toossi Z., Edmonds K.E., Tomford W.J., and Ellner J.J. (1989). Suppression of PPD-induced interleukin-2 production by interaction of CD 16 lymphocytes and adherent mononuclear cells in tuberculosis. *J Infect Dis.* **159**: 352-356.

Toossi Z., Kleinhenz M.E., and Ellner J.J. (1986). Defective interleukin-2 production and responsiveness in human pulmonary tuberculosis. *J Exp Med.* **163**: 1162-1172.

Toossi, Z. (1996). Cytokine circuits in tuberculosis. *Infectious Agents and Disease.* **5**: 98-107.

Townsend A., Ohlen C., and Bastin J. (1989). Association of class I major histocompatibility heavy and light chains induced by viral peptides. *Nature* **340**: 443-445.

Tracey K.J. and Cerami A. (1993^a). Tumor necrosis factor: an updated review of its biology. *Crit Care Med.* **21**: S415-22.

Tracey K.J. and Cerami A. (1993^b). Tumor necrosis factor, other cytokines and disease. *Annu Rev Cell Biol.* **9**: 317-43.

Trinchieri G. (1994). Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. *Blood.* **84**: 4008-27.

Trinchieri G. (1995). Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. *Annu Rev Immunol.* **13**: 251-76.

Trinchieri G. and Scott P. (1994). The role of interleukin 12 in the immune response, disease and therapy. *Immunol Today.* **15**: 460-3.

Trinchieri G. and Gerosa F.. (1996). Immunoregulation by interleukin-12. *J Leukocyte Biol.* **59**: 505-511.

Tse K.F., Morrow J.K., Hughes N.K., and Gallicchio V.S. (1994). Stromal cell lines derived from LP-BM5 murine leukemia virus-infected long-term bone marrow cultures impair hematopoiesis in vitro. *Blood* **84**: 1508-18.

Tsukaguchi K., Balaji K.N., and Boom W.H. (1995). CD4+ alpha beta T cell and gamma delta T cell responses to *Mycobacterium tuberculosis*. Similarities and differences in Ag recognition, cytotoxic effector function, and cytokine production. *J Immunol.* **154**:1786-96.

Umemura M., Hirose K., Wajjwaiku W., Nishimura H., Matsuguchi T., Gotoh Y., Takahashi M., Makino M., and Yoshikai Y. (2001). Impaired IL-15 production associated with susceptibility of murine AIDS to mycobacterial infection. *J Leukoc Biol.* **69**: 138-48.

Van Oss C.J. and Van Regelmortel M.H.V. (1994). *Immunochemistry*. Marcel Dekker, Inc. New York. Chapter 38.

Van Vlem B., Vanholder R., De Paepe P., Vogelaers D., and Ringoir S. (1996). Immunomodulating effects of antibiotics: literature review. *Infection.* **24**: 275-91.

Verschoor J.A. and Onyebujo P. (1999). The menace of the AIDS-tuberculosis combo: any solutions. *Bioessays* **21**: 365-6.

Vidal S.M, Malo D., Vogen K., Skamene E., and Gros P., (1993). Natural resistance to interferon with intracellular parasite: isolation of candidate for BCG. *Cell* **173**: 469-474.

Walker W., Roberts C.W., Ferguson D.J., Jebbari H., and Alexander J. (1997). Innate immunity to *Toxoplasma gondii* is influenced by gender and is associated with differences in interleukin-12 and gamma interferon production. *Infect Immun.* **65**: 1119-21.

Wallis R.S. Amir-Tahmasseb M. and Ellner J.J. (1990). Induction of interleukin1 and tumor necrosis factor by mycobacterial proteins: the monocyte western blot. *Proc Natl Acad Sci USA.* **87**: 3348-52.

Wallis R.S., Vjecha M., Amir-Tahmasseeb M., Okwera A., Byekwaso F., Nyole S., Kabengerwa S., Mugerwa R.D., and Ellner J.J. (1993). Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated beta 2-microglobulin in HIV-1-associated tuberculosis. *J Infect Dis.* **167**: 43-8.

Wang A.M., Doyle M.V., Mark D.F. (1989). Quantitation of mRNA by the polymerase chain reaction. *Proc Natl Acad Sci U S A.* **86**:9717-21.

Weltman J.K. and Davis R.P. (1970). Fluorescence polarization study of a human IgA myeloma protein: absence of segmental flexibility. *J Mol Biol.* **54**: 177-85.

Woolf S.F., Temple P.A., Kobayashi M., Young D., Diczig M., Lowe L., Dzialo R., Fitz L., Ferenz C., Hewich R.M., Kelleher K., Hermann S.H., Clark S.C., Azzoni L., Chan S.H., Trinchieri G., and Perussia B., (1991). Cloning cDNA for natural killer cell stimulatory factor , a heterodimeric cytokine with multiple biologic effect on T and natural killer cells. *J Immunol.* **146**: 3074-3080.

World Health Organization (WHO). At: <http://www.appliedbiosystems.com>

Yetter R.A., Buller R.M., Lee J.S., Elkins K.L., Mosier D.E., Fredrickson T.N., and Morse H.C. 3rd. (1988). CD4+ T cells are required for development of a murine retrovirus-induced immunodeficiency syndrome (MAIDS). *J Exp Med.* **168**:623-35.

Yoshida A., Koide Y. and Uchijima M. (1995). Dissection of strain difference in acquired protective immunity against *Mycobacterium bovis* Calmette-Guerin bacillus (BCG). Macrophages regulate the susceptibility through cytokine network and the induction of nitric oxide synthase. *J Immunol.* **155**: 2057-2066.

Young D.B., Ivanyi J., Cox J.H., and Lamb J.R. (1987) The 65kDa antigen of mycobacteria-a common bacterial protein? *Immunol Today* **8**: 215-219

Yuan Y, Crane DC, Musser JM, Sreevatsan S, Barry CE 3rd. (1997). MMAS-1, the branch point between cis- and trans-cyclopropane-containing oxygenated mycolates in *Mycobacterium tuberculosis*. *J Biol Chem.* **272**: 10041-9.

Zhang M., Gately M.K., Wang E., Gong J., Wolf S.F., Lu S., Modlin R.L., and Barnes P.F. (1994). Interleukin 12 at the site of disease in tuberculosis. *J Clin Chest Invest.* **93**: 1733-9

Zhang Y and Rom W.N. (1993). Regulation of interleukin-1 beta (IL-1 beta) gene by mycobacterial components and lipopolysaccharide is mediated by two nuclear factor IL-6 motifs. *Mol Cell Biol.* **13**: 3831-7.

Zheng X. and Roberts G.D. (1999). In: David Schlossberg (ed) *Tuberculosis* 4th edition. Springer-Verlag New York. 57-64.

Zimmerli S., Edwards S., and Ernst J.D. (1996). Selective receptor blockade during phagocytosis does not alter the survival and growth of *Mycobacterium tuberculosis* in human macrophages. *Am J Respir Cell Mol Biol.* **15**: 760-70.